- Home
- GILT vs BMEA Comparison
GILT vs BMEA Comparison
Compare GILT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILT
- BMEA
- Stock Information
- Founded
- GILT 1987
- BMEA 2017
- Country
- GILT Israel
- BMEA United States
- Employees
- GILT N/A
- BMEA N/A
- Industry
- GILT Radio And Television Broadcasting And Communications Equipment
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- GILT Technology
- BMEA Health Care
- Exchange
- GILT Nasdaq
- BMEA Nasdaq
- Market Cap
- GILT 334.1M
- BMEA 145.0M
- IPO Year
- GILT 1993
- BMEA 2021
- Fundamental
- Price
- GILT $6.11
- BMEA $3.79
- Analyst Decision
- GILT Strong Buy
- BMEA Buy
- Analyst Count
- GILT 2
- BMEA 13
- Target Price
- GILT $8.50
- BMEA $37.25
- AVG Volume (30 Days)
- GILT 475.2K
- BMEA 1.1M
- Earning Date
- GILT 02-24-2025
- BMEA 10-29-2024
- Dividend Yield
- GILT N/A
- BMEA N/A
- EPS Growth
- GILT 17.04
- BMEA N/A
- EPS
- GILT 0.29
- BMEA N/A
- Revenue
- GILT $302,932,000.00
- BMEA N/A
- Revenue This Year
- GILT $18.81
- BMEA N/A
- Revenue Next Year
- GILT $32.32
- BMEA N/A
- P/E Ratio
- GILT $21.19
- BMEA N/A
- Revenue Growth
- GILT 15.14
- BMEA N/A
- 52 Week Low
- GILT $4.04
- BMEA $3.61
- 52 Week High
- GILT $6.66
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- GILT 64.11
- BMEA 26.06
- Support Level
- GILT $5.69
- BMEA $3.74
- Resistance Level
- GILT $6.33
- BMEA $4.30
- Average True Range (ATR)
- GILT 0.19
- BMEA 0.40
- MACD
- GILT -0.01
- BMEA 0.01
- Stochastic Oscillator
- GILT 76.92
- BMEA 6.84
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs) and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.